The growing interest in potent weight management has led to considerable research into groundbreaking treatments. Recently , Retatrutide, a dual -action glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist , has demonstrated promising results in